Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
Board of Directors and Auditors of Krona14 Mar 2003
Marianne Dicander Alexandersson appointe12 Mar 2003
Orion Pharma taking actions to improve10 Mar 2003
Orion discontinues deramciclane studies18 Feb 2003
ORION GROUP FINANCIAL STATEMENTS BULLETI18 Feb 2003
BOARD OF DIRECTORS OF ORION PROPOSES MER18 Feb 2003
ORION CORPORATION SHARE REPURCHASE 29.0129 Jan 2003
ORION CORPORATION SHARE REPURCHASE 28.0128 Jan 2003
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
ORION CORPORATION SHARE REPURCHASE 27.0127 Jan 2003
ORION CORPORATION SHARE REPURCHASE 24.0124 Jan 2003
ORION CORPORATION SHARE REPURCHASE 23.0123 Jan 2003
ORION CORPORATION SHARE REPURCHASE 22.0122 Jan 2003
  • Previous
  • 1
  • More pages
  • 92
  • 93
  • 94
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130